**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 4)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 6)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 7)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>03/01/2021</td>
<td>A</td>
<td>4,397(1) A</td>
<td>$0</td>
<td>130,045(2) D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>03/01/2021</td>
<td>A</td>
<td>5,399(1) A</td>
<td>$0</td>
<td>135,438 D</td>
<td></td>
</tr>
<tr>
<td>Common Stock(10)</td>
<td>03/01/2021</td>
<td>A</td>
<td>3,373 A</td>
<td>$37.09</td>
<td>138,811 D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>03/01/2021</td>
<td>A</td>
<td>12,264(1) A</td>
<td>$0</td>
<td>151,075 D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>03/01/2021</td>
<td>F</td>
<td>2,199(1) D</td>
<td>$37.09</td>
<td>151,048 D</td>
<td></td>
</tr>
</tbody>
</table>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 4)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 5, 6, 7, 8)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 6 and 7)</th>
<th>8. Price of Derivative Security (Instr. 8)</th>
<th>9. Number of derivative Securities Beneficially Owned (D) or Indirectly Beneficially Owned (I) (Instr. 9)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 10)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Options (right to buy)</td>
<td>$37.09</td>
<td>03/01/2021</td>
<td>A</td>
<td>2,199</td>
<td>03/01/2021(1) 03/01/2024(2) Common Stock</td>
<td>2,199</td>
<td>$37.09</td>
<td>0</td>
<td>2.199</td>
<td>D</td>
</tr>
</tbody>
</table>

**Explanations**:

1. Subject to the terms and conditions of the applicable award agreement, these restricted stock units are scheduled to settle in stock as follows: 100% on the third anniversary of the grant date.

2. Includes an additional 4,063 shares acquired through a dividend reinvestment program.

3. Subject to the terms and conditions of the applicable award agreement, these restricted stock units are scheduled to settle in stock as follows: 75% on the third anniversary of the grant date and the remaining 25% on the fourth anniversary of the grant date.

4. Common stock issued pursuant to the compensation committee-approved Issuer’s Bonus Swap Program.

5. Subject to the terms and conditions of the applicable award agreement, these restricted stock units awarded pursuant to the Issuer’s Bonus Swap Program are scheduled to settle in stock as follows: 100% on the third anniversary of the grant date.

6. Withholding of shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

7. Options vest 100% on the third anniversary of the grant date, subject to the terms and conditions of the stock option award agreement.

8. Options vest 100% on the third anniversary of the grant date, subject to the terms and conditions of the stock option award agreement.

9. Options vest 100% on the third anniversary of the grant date, subject to the terms and conditions of the stock option award agreement.

10. Options vest 100% on the third anniversary of the grant date, subject to the terms and conditions of the stock option award agreement.

11. Options vest 100% on the third anniversary of the grant date, subject to the terms and conditions of the stock option award agreement.

**Remarks**:

/\ Heidi Miller by Power of Attorney

Date
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby consents and appoints each of Ruthicia La Lande, Prasanth Akkapudi and person holding the title of Assistant Corporate Secretary of The Kroenheime Company signing singly, the undersigned’s true and lawful attorney-in-fact to:

(1) prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other document necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

(2) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer of The Kroenheime Company (the “Company”), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms with the SEC and any stock exchange or similar authority; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that such attorney-in-fact shall take no action without the undersigned’s written consent, except the undersigned authorizes, ratifies and confirms such action as requested by the undersigned, in accordance with this Power of Attorney.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

This Power of Attorney revokes all prior Powers of Attorney relating to reporting under Section 16 of the Securities Exchange Act of 1934 of the Company’s securities and shall remain in effect until revoked by a subsequently filed instrument.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of September, 2019.

[Signature]

Bruno Kelle